#transgene $TNG broke MA200#transgene $TNG broke MA200, closed on high volume. Could see a violent move into 1.75 and then above 2.00
Next report date
Report period
H1 2024
EPS estimate
—
Revenue estimate
—
−0.25USD
−24.64 MUSD
1.31 MUSD
35.03 M
About TRANSGENE
Sector
Industry
CEO
Alessandro Riva
Website
Headquarters
Strasbourg
Employees (FY)
158
Founded
1979
ISIN
FR0005175080
FIGI
BBG000J60807
Transgene SA is a biotechnology company that focuses on designing and developing targeted immunotherapies for the treatment of cancer. Its products include TG4001, TG4050, TG6002, BT-001 & TG6050. The company was founded in December 1979 and is headquartered in Strasbourg, France.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of TRGNF is 1.62 USD — it has decreased by 12.43% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange TRANSGENE S.A. stocks are traded under the ticker TRGNF.
TRANSGENE S.A. is going to release the next earnings report on Sep 24, 2024. Keep track of upcoming events with our Earnings Calendar.
TRGNF stock is 14.20% volatile and has beta coefficient of 0.14. Check out the list of the most volatile stocks — is TRANSGENE S.A. there?
TRGNF earnings for the last quarter are −0.17 USD per share, whereas the estimation was −0.23 USD resulting in a 23.81% surprise. The estimated earnings for the next quarter are −0.24 USD per share. See more details about TRANSGENE S.A. earnings.
TRANSGENE S.A. revenue for the last quarter amounts to 1.26 M USD despite the estimated figure of 7.31 M USD. In the next quarter revenue is expected to reach 7.40 M USD.
Yes, you can track TRANSGENE S.A. financials in yearly and quarterly reports right on TradingView.
TRGNF net income for the last quarter is −7.09 M USD, while the quarter before that showed −17.34 M USD of net income which accounts for 59.11% change. Track more TRANSGENE S.A. financial stats to get the full picture.
Today TRANSGENE S.A. has the market capitalization of 130.51 M, it has decreased by 1.12% over the last week.
No, TRGNF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TRGNF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TRANSGENE S.A. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 28, 2024, the company has 158.00 employees. See our rating of the largest employees — is TRANSGENE S.A. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TRANSGENE S.A. technincal analysis shows the sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TRANSGENE S.A. stock shows the sell signal. See more of TRANSGENE S.A. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on TRANSGENE S.A. future price: according to them, TRGNF price has a max estimate of 5.86 USD and a min estimate of 3.80 USD. Read a more detailed TRANSGENE S.A. forecast: see what analysts think of TRANSGENE S.A. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TRANSGENE S.A. EBITDA is −37.31 M USD, and current EBITDA margin is −2.86 K%. See more stats in TRANSGENE S.A. financial statements.